Managed Access Program (MAP): how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What MAP is

Origin and authorising body. Multi-jurisdictional manufacturer-led pattern, operating under each destination country's named-patient or compassionate-use legal basis. The authorising body for each individual case is the manufacturer (operationally) under destination-country regulator authorisation through the relevant named-patient or compassionate-use framework, acting under that jurisdiction's pharmacy or medicines legislation.

Legal basis. Managed Access Program is not a specific statutory framework; it is a commercial design pattern that manufacturers use to provide structured access to a medicine under managed conditions. The legal authorisation in each destination country comes from the relevant named-patient, compassionate-use, or expanded-access statute. The 'managed' element refers to the manufacturer's protocol structure (eligibility criteria, supply chain, monitoring, reporting) rather than a distinct regulatory tier.

Managed Access Programs are manufacturer-designed access pathways for medicines in defined access windows: pre-approval (between filing and authorisation), post-approval but pre-reimbursement, post-approval in jurisdictions where commercial launch is delayed, or post-withdrawal where the medicine remains needed by a defined patient group. The 'managed' element means the manufacturer establishes a single global or regional protocol with consistent eligibility, supply, and reporting requirements, then layers it on top of each destination country's legal framework.

MAPs are common in oncology, rare disease, and advanced therapy medicinal products. The manufacturer typically appoints a global access partner (a specialty pharmacy or third-party administrator) to operate the programme. Pricing under MAPs varies: some are free of charge, some operate at cost recovery, some operate at a discounted commercial price. Insurer reimbursement is typically separate from MAP pricing and depends on the destination country's payer landscape.

This page consolidates Reserve Meds's operational view of the Managed Access Program framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Managed Access Program-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use MAP

MAPs are used by treating physicians on behalf of patients who meet the manufacturer's published eligibility criteria. The patient must be in a jurisdiction the MAP covers, the prescribing physician must be appropriately credentialed, and the dispensing infrastructure must meet the MAP's quality requirements.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under MAP

Specialty oncology agents in pre-approval or pre-launch access windows, rare-disease biologics, advanced therapy medicinal products, and post-approval medicines in jurisdictions with delayed commercial launch.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Managed Access Program import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Managed Access Program framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Managed Access Program dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Managed Access Program clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Managed Access Program authorisation as the legal basis for import but does recognise a Managed Access Program authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A MAP application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Patient eligibility confirmation per the MAP protocol.
• Treating physician credential verification.
• Destination-country named-patient or compassionate-use authorisation.
• Informed consent.
• Monitoring and adverse event reporting per the MAP.
• Periodic safety and outcomes reporting to the manufacturer.

Typical timeline

Once the patient is confirmed eligible and the destination-country authorisation is in place, MAP supply is typically rapid (1 to 3 weeks). End-to-end including authorisation: 4 to 8 weeks.

Costs and reimbursement

Pricing varies by MAP. Some are free, some are cost-recovery, some are at discounted commercial prices. Insurer reimbursement is separate.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Managed Access Program cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Managed Access Program framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works